References
- Grosclaude P, Bossard N, Remontet L, et al. Survie des patients atteints de cancer en France. Étude des registres du réseau FRANCIM. Paris: Springer, 2007:406 pp
- Staber P, Langner S, Dornbusch HJ, et al. Antifungal management in cancer patients. Wien Med Wochenschr 2007;157:503-510
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359
- Cordonnier C, Pautas C, Maury S, et al. Chimioprophylaxie des infections fongiques en hématologie. Conférence de consensus commune SFAR, SPILF, SRLF (2004). Available at http://www.infectiologie.com/site/medias/_documents/consensus/antifongiques-court-04.pdf. Accessed 3 June 2009
- Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2008 Dec 9
- Chapuis F, Thiebaut A, Bataillard A, et al. Conséquences économiques d'une infection à aspergillus ou à autre champignons filamenteux chez les patients traités pour leucémie aiguë myéloïde et modélisation des stratégies préventives. J Mycol Med 2001;11:67-72
- Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34
- Jansen JP, Kern WV, Cornely OA, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9:12-23
- Wingard JR, Herbrecht R, Mauskopf J, et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis. 2007;9:182-188.
- Wenzel R, Del Favero A, Kibbler C, et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55:352-61
- Collins CD, Stuntebeck ER, DePestel DD, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Investig 2007;27:233-241
- Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008;65:2237-2243
- de Vries R, Daenen S, Tolley K, et al. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics 2008;26:75-90
- Ascioglu S, Rex JH, de Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14
- http://www.atih.sante.fr/openfile.php?id=1819 Accessed 3 June 2009
- http://seer.cancer.gov/ Accessed 9 March 2007
- Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006; 106:1099-1109
- http://www.insee.fr Accessed 3 June 2009
- Al-Badriyeh D, Slavin M, Liew D, et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother 2010;65:1052-1061
- Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole versus standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008;81:467-474